Inactive Instrument

POIT BIOP

Equities

RACA

US7305411099

POINT Biopharma Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 12, 2022 at 08:20 am EDT

POINT Biopharma Global Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 24.58 million compared to USD 8.8 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.15 a year ago.
For the six months, net loss was USD 40.96 million compared to USD 14.59 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.26 a year ago.

Latest news about POIT BIOP

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Biotechnology Select Industry Index	Dec. 29	CI
POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Global BMI Index	Dec. 29	CI
POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P TMI Index	Dec. 29	CI
Fusion Pharmaceuticals an 'Attractive' Takeover Target Following Recent Radiopharma Deals, Oppenheimer Says	Dec. 27	MT
Fusion Pharmaceuticals 'Last Available Target' With Solid Supply Chain After Point Biopharma, RayzeBio Takeovers, Oppenheimer Says	Dec. 27	MT
Swiss Shares Decline Amid Lingering Concerns for Growth of Local Economy	Dec. 27	MT
Eli Lilly: successful takeover bid for POINT Biopharma Global	Dec. 27	CF
Eli Lilly Completes Acquisition of Point Biopharma Global	Dec. 27	MT
Eli Lilly Completes Acquisition of POINT Biopharma Global	Dec. 27	MT
Eli Lilly Closes $1.4 Billion Takeover of Point Biopharma	Dec. 27	MT
POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from NASDAQ Composite Index	Dec. 27	CI
Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.	Dec. 26	CI
North American Morning Briefing : Dow Futures Fall -2-	Dec. 22	DJ
Brookline Capital Downgrades POINT Biopharma Global to Hold From Buy, Cuts Price Target to $12.50 From $27	Dec. 21	MT
Lantheus, POINT Biopharma Say Trial of 177Lu-PNT2002 for Metastatic Castration-Resistant Prostate Cancer Meets Endpoint	Dec. 18	MT
Eli Lilly Extends Tender Offer for POINT Biopharma Acquisition to Dec. 22	Dec. 18	MT
Eli Lilly: further extension of takeover bid for Point Biopharma Global	Dec. 18	CF
Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer	Dec. 18	CI
Eli Lilly Further Extends Tender Offer Deadline for Point Biopharma Shares	Dec. 18	MT
Eli Lilly: further extension of its tender offer for POINT Biopharma	Dec. 04	CF
Eli Lilly Extends Tender Offer for POINT Biopharma to Dec. 15	Dec. 04	MT
Eli Lilly Extends Tender Offer Period for Point Biopharma Global Acquisition	Dec. 04	MT
Eli Lilly extends tender offer to buy Point Biopharma	Dec. 04	RE
Eli Lilly: has extended its tender offer for Point Biopharma	Nov. 20	CF
Eli Lilly Extends Tender Offer for POINT Biopharma Acquisition	Nov. 17	MT

Chart POIT BIOP

Duration

Period

More charts

Company Profile

POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.

Sector

More about the company